Actively Recruiting
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Led by Anhui Provincial Hospital · Updated on 2024-05-21
25
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.
CONDITIONS
Official Title
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and ECOG performance status of 0 to 2
- Age over 18 years, any gender
- Confirmed esophageal squamous cell carcinoma by pathology or imaging
- Tumor recurrence after radical surgery or chemoradiotherapy, or regional progression after first- or second-line treatment
- Clinical staging showing regional recurrence or progression according to AJCC/UICC 8th edition
- Measurable tumor lesions
- Expected survival of at least 3 months
- Normal major organ function meeting specified blood and biochemical criteria
- Negative pregnancy test within 7 days before treatment for women of childbearing age
- Use of effective contraception during treatment and for 4 weeks after completion
- No serious defects in hematopoietic, heart, endocrine, or immune function
- No grade 3 or higher serious medical diseases other than esophageal cancer
You will not qualify if you...
- Under 18 years of age or ECOG greater than 2
- Esophageal cancer diagnosis not confirmed by pathology or imaging
- Salvage surgery after tumor recurrence
- Any active autoimmune disease or related conditions
- Use of immunosuppressants or systemic hormone therapy above specified doses within 2 weeks before enrollment
- Severe or uncontrolled grade 3 or higher diseases including blood pressure, heart conditions, infections, or liver diseases
- Pregnant or lactating women
- History of psychotropic drug abuse or untreated mental disorders
- Participation in other drug clinical trials within 4 weeks
- Refusal by patient or family to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yuan He
Hefei, China, 230001
Actively Recruiting
Research Team
Y
Yuan He, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here